D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 106 Citations 83,476 402 World Ranking 2936 National Ranking 1686

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Surgery

Roger Stupp spends much of his time researching Internal medicine, Temozolomide, Oncology, Surgery and Randomized controlled trial. His study on Clinical endpoint and Survival rate is often connected to Procarbazine and Lomustine as part of broader study in Internal medicine. His research in Temozolomide intersects with topics in Cancer and Dacarbazine.

His studies deal with areas such as Interim analysis, Clinical trial, Phases of clinical research and Survival analysis as well as Oncology. Roger Stupp has researched Surgery in several fields, including Anaplastic astrocytoma and Hazard ratio. The various areas that he examines in his Radiation therapy study include Concomitant, Chemotherapy regimen and Confidence interval.

His most cited work include:

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma (12592 citations)
  • MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma (4767 citations)
  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (4693 citations)

What are the main themes of his work throughout his whole career to date?

Roger Stupp mainly investigates Internal medicine, Oncology, Temozolomide, Surgery and Radiation therapy. Roger Stupp combines subjects such as Glioblastoma and Glioma with his study of Internal medicine. While the research belongs to areas of Oncology, Roger Stupp spends his time largely on the problem of Cancer, intersecting his research to questions surrounding Progression-free survival.

The study incorporates disciplines such as Anaplastic astrocytoma, Cilengitide, Adjuvant, Survival analysis and Dacarbazine in addition to Temozolomide. His Surgery study frequently draws parallels with other fields, such as Hazard ratio. His Chemotherapy research incorporates themes from Gastroenterology and Lung cancer.

He most often published in these fields:

  • Internal medicine (61.90%)
  • Oncology (56.19%)
  • Temozolomide (36.00%)

What were the highlights of his more recent work (between 2016-2021)?

  • Internal medicine (61.90%)
  • Oncology (56.19%)
  • Cancer research (15.24%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Oncology, Cancer research, Temozolomide and Glioma. His Internal medicine research includes elements of Surgery and Glioblastoma. His Oncology research is multidisciplinary, relying on both Radiation therapy and Hazard ratio.

His research on Temozolomide concerns the broader Chemotherapy. His Glioma study integrates concerns from other disciplines, such as Cancer, Immunotherapy, Methylation, DNA methylation and Pharmacology. His study looks at the relationship between Randomized controlled trial and fields such as Survival analysis, as well as how they intersect with chemical problems.

Between 2016 and 2021, his most popular works were:

  • Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (578 citations)
  • Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (578 citations)
  • Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (578 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Chemotherapy

Roger Stupp focuses on Internal medicine, Oncology, Temozolomide, Glioblastoma and Cancer research. Pembrolizumab is closely connected to Surgery in his research, which is encompassed under the umbrella topic of Internal medicine. His Oncology research incorporates elements of Cancer, Anaplastic astrocytoma, DNA mismatch repair and Hazard ratio.

His study in Cancer is interdisciplinary in nature, drawing from both Radiation therapy and Immune system. His Temozolomide study incorporates themes from Interim analysis, Clinical trial and Combined Modality Therapy. In general Glioblastoma study, his work on Astrocytic glioma often relates to the realm of In patient and Tert promoter, thereby connecting several areas of interest.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller.
The New England Journal of Medicine (2005)

16946 Citations

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent.
Lancet Oncology (2009)

7623 Citations

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Monika E Hegi;Annie-Claire Diserens;Thierry Gorlia;Marie-France Hamou.
The New England Journal of Medicine (2005)

6490 Citations

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy.
Journal of Clinical Oncology (2010)

2941 Citations

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

T Le Chevalier;R Arriagada;C Le Pechoux;D Grunenwald.
The New England Journal of Medicine (2004)

2874 Citations

Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide

Roger Stupp;Pierre Yves Dietrich;Sandrine Ostermann Kraljevic;Alessia Pica.
Journal of Clinical Oncology (2002)

1077 Citations

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Annika Malmström;Bjørn Henning Grønberg;Christine Marosi;Roger Stupp.
Lancet Oncology (2012)

959 Citations

Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

Monika E. Hegi;Annie Claire Diserens;Sophie Godard;Pierre Yves Dietrich.
Clinical Cancer Research (2004)

885 Citations

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

Monika E. Hegi;Lili Liu;James G. Herman;Roger Stupp.
Journal of Clinical Oncology (2008)

849 Citations

Maintenance therapy with tumor-Treating fields plus temozolomide vs temozolomide alone for glioblastoma a randomized clinical trial

Roger Stupp;Roger Stupp;Sophie Taillibert;Andrew A. Kanner;Santosh Kesari.
JAMA (2015)

794 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Roger Stupp

Patrick Y. Wen

Patrick Y. Wen

Harvard University

Publications: 306

Wolfgang Wick

Wolfgang Wick

German Cancer Research Center

Publications: 286

Michael Weller

Michael Weller

University of Zurich

Publications: 277

David A. Reardon

David A. Reardon

Harvard University

Publications: 223

Timothy F. Cloughesy

Timothy F. Cloughesy

University of California, Los Angeles

Publications: 201

Mark R. Gilbert

Mark R. Gilbert

The University of Texas MD Anderson Cancer Center

Publications: 159

Susan M. Chang

Susan M. Chang

University of California, San Francisco

Publications: 156

Jeremy N. Rich

Jeremy N. Rich

University of Pittsburgh

Publications: 154

Andreas von Deimling

Andreas von Deimling

Heidelberg University

Publications: 142

Martin J. van den Bent

Martin J. van den Bent

Erasmus University Rotterdam

Publications: 137

John H. Sampson

John H. Sampson

Duke University

Publications: 126

Kenneth D. Aldape

Kenneth D. Aldape

Princess Margaret Cancer Centre

Publications: 117

Mitchel S. Berger

Mitchel S. Berger

University of California, San Francisco

Publications: 115

Tao Jiang

Tao Jiang

Capital Medical University

Publications: 113

Guido Reifenberger

Guido Reifenberger

Heinrich Heine University Düsseldorf

Publications: 112

Pieter Wesseling

Pieter Wesseling

University of Amsterdam

Publications: 110

Something went wrong. Please try again later.